Among patients with prostate cancer, PSA values were above 4 at the beginning of the study in 78.6% of included patients – this value decreased to 73.6% after one year (of course excluding drop-outs), which cannot be attributed merely to the specific cancer therapy but also to zoledronic acid treatment. Here, KLK3 is linked to prostate carcinoma.